Lyell Immunopharma Inc
General ticker "LYEL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $213.0M
Lyell Immunopharma Inc does not follow the US Stock Market performance with the rate: -25.8%.
Estimated limits based on current volatility of 5.9%: low 0.56$, high 0.63$
Factors to consider:
- Current price 57.7% below estimated low
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.45$, 3.14$]
- 2024-12-30 to 2025-12-30 estimated range: [1.51$, 3.23$]
Short-term LYEL quotes
Long-term LYEL plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $12.97MM | $89.44MM | $2.92MM |
| Operating Expenses | $227.75MM | $276.50MM | $249.93MM |
| Operating Income | $-214.78MM | $-187.06MM | $-247.01MM |
| Non-Operating Income | $-35.44MM | $3.94MM | $12.38MM |
| R&D Expense | $138.69MM | $159.19MM | $182.94MM |
| Income(Loss) | $-250.22MM | $-183.12MM | $-234.63MM |
| Profit(Loss) | $-250.22MM | $-183.12MM | $-234.63MM |
| Stockholders Equity | $929.79MM | $833.25MM | $654.95MM |
| Assets | $1,127.41MM | $937.56MM | $750.03MM |
| Operating Cash Flow | $-126.25MM | $-169.56MM | $-163.69MM |
| Capital expenditure | $65.50MM | $24.28MM | $2.69MM |
| Investing Cash Flow | $-121.57MM | $-11.54MM | $184.05MM |
| Financing Cash Flow | $401.24MM | $10.63MM | $1.74MM |
| Earnings Per Share* | $-1.18 | $-0.02 | $-0.93 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.